Q-omics provides the consensus-scored BCL2L1 profile across patient tissues and cancer cell-line models. BCL2L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, BCL2L1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, BCL2L1 RNA expression shows 18,273 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, COAD, and ACC as cancer lineages where BCL2L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2L1 survival associations across molecular data types. BCL2L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2L1 RNA expression–survival associations across cancer types. High BCL2L1 expression shows unfavorable associations in PAAD, LGG and UVM, but favorable associations in UCS, THYM and BRCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for BCL2L1 RNA expression.
This table summarizes BCL2L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BCL2L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2L1 shows higher tumor expression in COAD, THCA, STAD, LIHC, KIRP and BRCA. The COAD box plot shows higher BCL2L1 RNA expression in tumor versus normal tissue (log2 FC = +1.245, t-test p < 0.001).
This table shows molecular features associated with BCL2L1 in patient tissues and cancer cell lines. In patient samples, BCL2L1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
